세계의 중재적 신경영상의학 시장 규모는 2024년에 311억 9,887만 달러로, 2032년까지 520억 8,152만 달러에 달할 것으로 예측되며, 2025-2032년의 예측 기간에 CAGR로 6.66%의 성장이 전망됩니다. 중재적 신경영상의학 수요는 주로 신경질환, 특히 뇌동맥류, 허혈성 뇌졸중, 동정맥 기형(AVM)의 유병률 증가에 의해 촉진되고 있습니다. 이러한 질환의 유병률이 증가함에 따라 환자 예후를 개선하고 회복 시간을 단축하는 최소침습적 진단 및 치료 기법의 필요성이 증가하고 있습니다.
또한 기술 발전은 예측 기간(2025-2032년) 동안 시장 성장을 가속하는 데 매우 중요한 역할을 할 것으로 예상됩니다. 차세대 유량 전환기, 유연한 마이크로카테터, 향상된 이미징 기술, 로봇 보조 중재술 등의 개발로 인해 중재적 신경 방사선 시술의 정확성, 안전성, 유효성이 크게 향상되고 있습니다. 이러한 발전으로 이전에는 수술이 불가능하거나 수술 위험이 높다고 여겨졌던 복잡한 신경질환을 치료할 수 있게 되었습니다.
또한 영상 진단에 AI와 머신러닝 알고리즘의 통합은 조기 발견 및 치료 계획을 강화하고 중재적 신경방사선학 솔루션의 채택을 촉진하고 있습니다. 저침습적 시술에 대한 선호도가 높아지면서 환자의 인식이 높아지고 의료 인프라가 개선됨에 따라 다양한 지역에서 시장 확대가 가속화되고 있습니다.
중재적 신경영상의학 시장 역학
중재적 신경방사선치료 시장은 신경질환의 유병률 증가, 뇌졸중 발병률 증가, 치료 장비의 지속적인 기술 발전으로 인해 예측 기간 중 크게 성장할 것으로 예상됩니다.
Brain Aneurysm Foundation(2023)에 따르면 미국에는 약 670만 명이 파열되지 않은 뇌동맥류가 있으며, 연간 약 3만 건의 동맥류 파열이 보고되고 있습니다. 뇌동맥류 파열은 지주막하 출혈과 같은 생명을 위협하는 질환으로 이어질 수 있으며, 혈관내 코일 색전술이나 유량 전환기 사용과 같은 긴급한 중재적 시술이 필요합니다. 뇌동맥류의 유병률이 증가함에 따라 뇌동맥류에 대한 인식이 높아지고 진단 능력이 향상되었으며, 이에 따라 첨단 중재적 신경방사선(INR) 장비에 대한 수요도 증가하고 있습니다. 조기 발견 및 치료는 사망률을 크게 낮추고 장기적인 결과를 개선하여 시장 성장을 더욱 촉진하고 있습니다.
Global Stroke Fact Sheet(2022)에 따르면 2022년 전 세계에서 약 1,222만 건의 뇌졸중이 발생하며, 그 중 760만 건 이상이 허혈성 뇌졸중으로 전체 뇌졸중의 62%를 차지합니다. 허혈성 뇌졸중은 동맥의 막힘으로 인해 발생하며, 기계적 혈전제거술이나 스텐트 회수술과 같은 중재적 신경방사선술은 혈류를 회복하고 장기적인 장애의 위험을 줄이는 데 필수적입니다. 적시에 개입하면 환자의 회복과 생존율을 크게 향상시킬 수 있으므로 응급의료 현장에서 INR 시술의 채택이 증가하고 있습니다.
중재적 신경방사선학 분야의 기술 혁신은 시장 확대를 더욱 촉진하고 있습니다. 이러한 발전에는 유연성, 내구성, 생체적합성을 개선한 차세대 스텐트 및 유량 전환기의 개발이 포함되며, 이를 통해 성능이 향상되고 스텐트내 혈전증 및 장비 이동과 같은 합병증이 감소하고 있습니다. 또한 마이크로카테터와 마이크로 가이드와이어의 혁신으로 뇌의 복잡한 혈관망을 통과하는 정확도와 성공률이 향상되어 복잡한 동맥류와 동정맥 기형(AVM)을 보다 안전하고 효과적으로 치료할 수 있게 되었습니다. 로봇 보조 중재시술과 실시간 영상화 등 첨단 기술은 회복 시간을 단축하고 위험을 줄이는 최소침습적 시술이 가능해져 환자와 의료진 모두에게 점점 더 선호되고 있습니다.
이러한 긍정적인 요인에도 불구하고 시장은 중재적 장비와 관련된 합병증(혈관 천공, 장비 이동, 혈전색전증 등)과 장비 승인에 대한 까다로운 규제 환경과 같은 문제에 직면해 있습니다. 규제 당국은 안전성과 유효성을 보장하기 위해 광범위한 임상 데이터를 요구하므로 제품 출시가 지연되고 개발 비용이 증가할 수 있습니다.
그럼에도 불구하고 전 세계에서 신경 및 뇌혈관 질환의 부담이 증가하고, 조기 개입의 이점에 대한 인식이 높아지고, 지속적인 기술 발전이 과제를 능가하면서 2025-2032년의 예측 기간 중 중재적 신경방사선치료 시장의 성장을 가속할 것으로 예상됩니다.
세계의 중재적 신경방사선학 시장에 대해 조사분석했으며, 시장 규모와 예측, 과거 3년의 제품/기술개발, 시장의 주요 기업, 이용 가능한 기회 등의 정보를 제공하고 있습니다.
Interventional Neuroradiology Market by Device (Micro guidewires, Microcatheters, Flow Diversion Stents, Embolization Coils, Neurovascular Embolization Devices, and Others), Disease (Cerebral Aneurysms, Intra-cranial Tumors, Acute Ischemic Strokes, and Other Diseases), End-Users (Hospitals, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the rising incidence of neurological disorders such as cerebral aneurysms and growing technical advancements in the domain of interventional neuroradiology
The interventional neuroradiology market was valued at USD 31,198.87 million in 2024, growing at a CAGR of 6.66% during the forecast period from 2025 to 2032 to reach USD 52,081.52 million by 2032. The demand for interventional neuroradiology is primarily driven by the rising incidence of neurological disorders, particularly cerebral aneurysms, ischemic strokes, and arteriovenous malformations (AVMs). The growing prevalence of these conditions has heightened the need for minimally invasive diagnostic and therapeutic procedures to improve patient outcomes and reduce recovery times.
Additionally, advancements in technology are playing a pivotal role in propelling market growth during the forecast period (2025 to 2032). Innovations such as the development of next-generation flow diversion devices, highly flexible microcatheters, enhanced imaging technologies, and robot-assisted interventions have significantly improved the precision, safety, and efficacy of interventional neuroradiology procedures. These advancements have enabled the treatment of complex neurological conditions that were previously considered inoperable or carried higher surgical risks.
Furthermore, the integration of artificial intelligence (AI) and machine learning algorithms in diagnostic imaging is enhancing early detection and treatment planning, thereby driving the adoption of interventional neuroradiology solutions. The increasing preference for minimally invasive procedures, combined with rising patient awareness and improved healthcare infrastructure, is further accelerating market expansion across various regions.
Interventional Neuroradiology Market Dynamics:
The interventional neuroradiology market is projected to experience significant growth during the forecast period, driven by the rising prevalence of neurological disorders, increasing incidence of strokes, and ongoing technological advancements in treatment devices.
According to the Brain Aneurysm Foundation (2023), approximately 6.7 million people in the United States have an unruptured brain aneurysm, with around 30,000 cases of aneurysm rupture reported annually. Brain aneurysm ruptures can lead to life-threatening conditions such as subarachnoid hemorrhage and require urgent interventional procedures like endovascular coiling or the use of flow diverters. The increasing prevalence of brain aneurysms has resulted in heightened awareness, improved diagnostic capabilities, and a corresponding rise in demand for advanced interventional neuroradiology (INR) devices. Early detection and treatment significantly reduce mortality and improve long-term outcomes, further propelling market growth.
Stroke prevalence is another critical factor fueling market demand. According to the Global Stroke Fact Sheet (2022), there were approximately 12.22 million incident stroke cases globally in 2022, with over 7.6 million ischemic strokes accounting for 62% of all strokes. Ischemic strokes occur due to blocked arteries, and interventional neuroradiology techniques such as mechanical thrombectomy and stent retrievers are essential in restoring blood flow and reducing the risk of long-term disability. Timely interventions significantly improve patient recovery and survival rates, which has boosted the adoption of INR procedures across emergency care settings.
Technological innovations in the interventional neuroradiology field further support market expansion. Advancements include the development of next-generation stents and flow diverters with improved flexibility, durability, and biocompatibility, which enhance performance and reduce complications such as in-stent thrombosis or device migration. Moreover, innovations in microcatheter and microguidewire technologies have improved precision and navigability through the brain's complex vascular network, allowing for safer and more effective treatment of complex aneurysms and arteriovenous malformations (AVMs). Cutting-edge technologies like robot-assisted interventions and real-time imaging advancements are also enabling minimally invasive procedures with shorter recovery times and reduced risks, which are becoming increasingly preferred by both patients and healthcare providers.
Despite these positive drivers, the market faces challenges such as complications associated with interventional devices (e.g., vessel perforation, device migration, or thromboembolic events) and the stringent regulatory landscape for device approval. Regulatory authorities require extensive clinical data to ensure safety and efficacy, which can delay product launches and increase development costs.
Nevertheless, the rising global burden of neurological and cerebrovascular diseases, increasing awareness of early intervention benefits, and continuous technological progress are expected to outweigh the challenges, thereby propelling the growth of the interventional neuroradiology market during the forecast period from 2025 to 2032.
Interventional Neuroradiology Market Segment Analysis:
Interventional Neuroradiology Market by Device (Micro guidewires, Microcatheters, Flow Diversion Stents, Embolization Coils, Neurovascular Embolization Devices, and Others), Disease (Cerebral Aneurysms, Intra-cranial Tumors, Acute Ischemic Strokes, and Other Diseases), End-Users (Hospitals, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)
In the device segment of the interventional neuroradiology market, the flow diversion stents category is projected to amass a significant revenue share in 2024, driven by their versatile applications, clinical advantages, and increasing product approvals that are collectively fueling market demand during the forecast period.
Flow diversion stents have emerged as a preferred treatment option for managing complex intracranial aneurysms, particularly those that are large, wide-necked, or fusiform cases that are challenging to treat with traditional methods such as endovascular coiling. These stents work by redirecting blood flow away from the aneurysm sac, promoting endothelial growth along the stent, and ultimately sealing off the aneurysm over time. Flow diversion therapy is especially beneficial for aneurysms that have recurred after previous treatments, offering a reliable alternative with long-term durability and lower recurrence rates.
One of the key benefits of flow diversion stents is their minimally invasive nature. The procedure is typically performed using a catheter-based delivery system through the femoral or radial artery, reducing the risks associated with open craniotomy and shortening recovery times. Unlike traditional coiling, direct manipulation of the aneurysm sac is avoided, significantly reducing the risk of rupture during the procedure. Moreover, many flow diversion techniques do not require adjunctive devices like coils or balloons, simplifying the intervention process and minimizing device-related complications.
The market growth for flow diversion stents is further fueled by a surge in product approvals and technological advancements. For instance, in December 2023, MicroPort(R) NeuroTech(TM) received approval from the Brazilian National Health Surveillance Agency (ANVISA) for its Tubridge(R) Vascular Reconstruction Device. The Tubridge(R) is a dense-mesh stent applying flow diversion therapy principles, designed specifically to treat large or giant wide-necked intracranial aneurysms. Such innovations offer improved device flexibility, better wall apposition, and enhanced navigability through tortuous cerebral vessels, making them suitable for treating complex cases with greater precision and safety.
Additionally, the rising prevalence of intracranial aneurysms, increased awareness of early diagnosis, and growing demand for minimally invasive interventions are key contributors to the expanding market share of flow diversion stents. As more healthcare facilities adopt these advanced devices and as clinical guidelines increasingly support their use for various aneurysm types, the adoption rate is expected to rise globally.
Therefore, owing to the aforementioned factors including their clinical efficacy, safety profile, technological advancements, and regulatory approvals the flow diversion stents category is poised to register significant growth, thereby driving the overall expansion of the interventional neuroradiology market during the forecast period (2025 to 2032).
North America is expected to dominate the overall interventional neuroradiology market:
North America is anticipated to account for the largest share of the interventional neuroradiology market in 2024, driven by a large patient pool affected by ischemic strokes, transient ischemic attacks (TIA), and a growing geriatric population. Additional factors such as advanced healthcare infrastructure, technological innovations, and robust product development pipelines are further propelling market growth in the region.
According to the Centers for Disease Control and Prevention (CDC) 2023, approximately 795,000 people in the United States experience a stroke each year, with 87% being ischemic strokes caused by a blockage of blood flow to the brain. The high prevalence of ischemic strokes, coupled with the need for rapid intervention to improve patient outcomes, has increased the demand for interventional neuroradiology devices, including mechanical thrombectomy devices, stent retrievers, and aspiration catheters.
The aging population in North America further contributes to the rising incidence of strokes and TIAs. According to the US Census Bureau 2021 report, over 54 million adults aged 65 and older were living in the United States in 2021. This demographic is expected to rise to approximately 85.7 million by 2050, representing nearly 20% of the overall US population. The elderly population, particularly those above 50 years, are at a higher risk of ischemic strokes and TIA due to age-related vascular changes such as arterial narrowing, arteriosclerosis, and atherosclerosis. This underscores the growing need for minimally invasive treatments to manage these conditions effectively.
Additionally, the high adoption rate of innovative technologies and the presence of major market players in the region foster continuous product launches and regulatory approvals. For example, the United States Food and Drug Administration (FDA) has expedited the approval of various neurovascular devices to enhance stroke care. The region's robust research and development activities, favorable reimbursement policies, and widespread use of advanced imaging technologies further support early diagnosis and prompt intervention, contributing to market expansion.
The strategic collaborations between healthcare providers, academic institutions, and medical device manufacturers in North America also play a crucial role in accelerating product innovations and expanding treatment accessibility. Moreover, the increasing awareness of stroke symptoms and improved emergency medical services are enabling faster treatment initiation, which is critical in ischemic stroke management.
Therefore, the combination of a growing stroke patient population, an aging demographic, technological advancements, and a supportive regulatory environment positions North America as the leading region in the interventional neuroradiology market during the forecast period (2025 to 2032).
Interventional Neuroradiology Market Key Players:
Some of the key market players operating in the interventional neuroradiology market include Stryker, Boston Scientific Corporation, MicroVention Inc., Cook, Mediterra, Johnson & Johnson, Inc., Merit Medical Systems, Inc., Terumo Corporation, Penumbra, Inc., MicroPort Scientific Corporation, Balt Group, AngioDynamics, Acandis GmBH, Phenox, and InspireMD Inc.
Recent Developmental Activities in the Interventional Neuroradiology Market:
Key Takeaways from the Interventional Neuroradiology Market Report Study
Target Audience Who Can be Benefited from this Interventional Neuroradiology Market Report Study
Frequently Asked Questions for the Interventional Neuroradiology Market: